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Abstract The design, synthesis and activity of poly-
modal compounds for the treatment of inflammatory
bowel disease are reported. The compounds, being
based on a metal-Schiff base motif, are designed to
degrade during intestinal transit to release the bioactive
components in the gut. The compounds have been
developed sequential with the biomodal compounds
combining copper or zincwith a salicylaldehyde adduct.
These compounds were tested in a formalin induced
colonic inflammation model in BK:A mice. From these
studies a trimodal compound based on a zinc Schiff base
analogue of sulfasalazine was designed. This was tested
against a trinitrobenzenesulfonic acid (TNB) induced
colitic model in Wistar rats. The use of two models
allows us to test our compounds in both an acute and a
chronic model. The trimodal compound reported is
observed to provide anticolitic properties in the chronic
TNB induced colitis model commensurate with that of
SASP. However, the design of trimodal compound still
has the capacity for further development. This the
platform reported may offer a route into compounds
which can markedly outperform the anti-colitic proper-
ties of SASP.
Keywords Ulcerative colitis  Polymodal drugs 
Sulfasalazine  Metal Schiff base compounds 
Formalin induced colonic inflammation  TNB
induced colonic inflammation
Introduction
The two most important chronic inflammatory bowel
diseases (IBD) are ulcerative colitis and Crohns
colitis, with ulcerative colitis accounting for 65–85%
of the total incidence of IBD (Shivananda et al. 1996;
Burisch and Munkholm 2015). Both forms of colitis
have an uncertain aetiology but have many features in
common. Both are debilitating chronic diseases sub-
ject to exacerbations and remission, and both involve
an immune component. The commonest symptoms are
bloody diarrhoea, rectal bleeding, anorexia and weight
loss. The colon shows extensive ulceration and there
may be abscess formation (Kirsner and Shorter 1982).
A severe attack can cause pathological colonic
distension known as toxic dilation, or ulcer perforation
resulting in faecal release into the abdomen. Both
conditions are associated with high mortality (Son-
nenberg 1990; Kassam et al. 2014).
There are few drugs available to treat IBD. The
currently used non-steroidal anti-colitic compounds
are all pro-drug formulations for 5-aminosalicylic acid
(5-ASA, Fig. 1), which has to be delivered to the colon
for its therapeutic effect (Friend 1991; Podolsky 2002;
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Furfaro et al. 2015). Orally administered 5-ASA is
unstable in the acid environment of the stomach, and is
also readily absorbed into the gastrointestinal tract
before reaching the colon. The oldest of the 5-ASA
prodrugs and still the main stay of maintenance
therapy for colitis, is salicylazosulfapyridine (sul-
fasalazine, SASP, Fig. 1). This was developed by
Svartz as an anti-rheumatic drug and found by chance
to have a beneficial effect on colitis patients (Svartz
1942). When taken by mouth, 75–90% of the SASP
reaches the colon intact where bacterial action cleaves
the azo-bond to release 5-ASA. However, the sul-
fapyridine carrier is also absorbed through the colon
wall and can produce toxic side effects as a result.
Attempts have been made to develop new formu-
lations in an attempt to deliver 5-ASA to the colon
using less toxic carriers (Friend 1991). Thus far none
of these formulations is more active than SASP.
Treatment with all of these drugs is frequently
discontinued due to their limited effectiveness and
because patients may show hypersensitivity reactions
and other side effects. Currently, all that remains to
such patients is treatment with cortico-steroids or
immuno-suppressants such as azathipine, both
approaches being accompanied by adverse systemic
side effects. Until new chemical entities or biologics
are identified (Danese et al. 2015; Hagan and Cross
2015), surgery will remain a common outcome if the
attacks recur (Sorenson 1976; Milanino et al. 1985).
It is clear that new drugs are needed for controlling
the symptoms and preventing the tissue damage
associated with IBD. Metal complexes of active
substances are useful lead compounds because certain
metals such as copper and zinc have some biological
activity and because as centres they can help protect
the active drug in the stomach and assist its delivery to
the colon (Sorenson 1976, 1977; Milanino et al. 1985;
Dillon et al. 2004).
Copper complexes (e.g. copper salicylate) have
been investigated as anti-arthritic and anti-ulcer agents
and have demonstrated a positive benefit in a number
of animal models of inflammation and inflammatory
conditions (Sorenson 1976, 1977). In the absence of a
detailed mechanism for their action a working hypoth-
esis has been put forward which involves the forma-
tion of copper chelate complexes in the plasma that are
responsible for the observed anti-inflammatory activ-
ity. However, it has also been suggested that the
activation of copper dependant processes assists in
wound and tissue repair (Borkow et al. 2008, 2010).
Alternatively or additionally, the anti-inflammatory
and anti-ulcer activity of copper complexes could be
Fig. 1 The structures of 5-ASA, SASP and the polymodal
Schiff base complexes under study here for their anti-colitic
properties. These Schiff base moieties potentially combine the
activities of 5-ASA (in its reduced form) with a biologically
relevant metal (M = Cu, Zn). The hydrolytically sensitive
Schiff base linkage is generated via an interaction with a third
entity (a simple amino acid in this study). The use of the reduced
form of salicylic acid to form the Schiff base linkage allows the
aniline residue of 5-ASA to be modified further and in line with
SASP
424 Biometals (2017) 30:423–439
123
associated with the dismutation of the superoxide
radical anion, which is routinely implicated in oxida-
tive tissue damage. The therapeutic role of zinc has
been studied less extensively than copper. Zinc
deficiency has been related to poor would healing
and zinc concentrations in peripheral blood cells are
lower than normal in patients with inflammatory
diseases such as rheumatoid arthritis (Svenson et al.
1985; Lansdown et al. 2007; Binneboesel et al. 2010;
Hwang et al. 2012). Indeed zinc deficiency has been
suggested to play a role in the formation and clinical
course of fistulas in Crohns disease and a reason for
poor would healing in inflammatory bowel disease
(Kruis et al. 1985; Binneboesel et al. 2010; Hwang
et al. 2012).
The search for new anti-colitic agents is hindered
by the an incomplete picture of the aetiology of
inflammatory bowel disease and the availability of
representative animal models for the testing of such
agents. Another factor to be considered is the
targeting of the anti-colitic agent to the colon when
oral administration is the preferred mode of delivery.
There are two main approaches to colon specific drug
delivery namely the use of metabolic events catal-
ysed by the gut microflora or the use of enteric
coatings (e.g. PENTASA, Asacol) which have
disintegration profiles based on the natural pH
gradient along the gastrointestinal tract. Both aid
the release of the active agents at the inflamed sites in
the colon (Friend 1991). Localisation of 5-ASA
release from these preparations is primarily depen-
dant on transit time. Transit through the colon is
considerably slower than through the small intestine
and can range from 10 h to as long as 78 h (Wyman
et al. 1978). However, transit times can be expected
to be more rapid during an episode of the symptoms
associated with IBD.
Parashar and co-workers have synthesised a series
of Schiff base complexes derived from salicyaldehyde
and 2-substituted analines (Parashar et al. 1989). The
copper chelates did not show significant anti-inflam-
matory activity on carrageenan induced oedema and
formaldehyde induced arthritis. Significantly, the
copper complex of salicylidene and anthranilic acid
was reported to possess anti-ulcer and anti-diarrhoeal
activity (Sorenson 1976, 1977; Kruis et al. 1985). In
contrast and more recently Alafeey et al. have reported
on quinazolinone Schiff bases which have some anti-
colitic activity (Alafeefy et al. 2015). Since it is
possible to build these complexes from a series of
active agents it is possible to quickly alter their
biological effects and make them bi-and tri-modal
such that they respond to the local gut microflora or
local pH for activation. Furthermore the relative
insolubility of metal Schiff base complexes may
satisfy the requirements for new oral therapeutic
agents for the treatment of IBD which have to survive
transit through the digestive system. It has been
demonstrated that metal complexes can be more
potent than the parent ligands (Sorenson
1976, 1977). If this is true for Schiff base complexes
then hydrolysis of the complex to its basic components
in colon may not be essential to confer activity.
We aim to test the effectiveness of metal Schiff
base complexes in controlling chronic inflammation.
There is the potential for each part of the Schiff base
molecule to comprise an anti-inflammatory agent
with a different mode of action. This approach to
combination therapy may be useful in conditions
such as ulcerative colitis, which has a range of
inflammatory mediators promoting the inflammatory
process.
Experimental
Unless otherwise stated the chemicals used were
commercially obtained. Infra red spectra were
recorded on a Perkin Elmer 457 grating infra-red
spectrophotometer. 1HNMR spectra were recorded on
a Bruker 250 MHz instrument. U.V. visible spectra
were recorded on a Phillips PU8740 spectrometer.
Preparation of zinc complexes
Salicylaldehyde (0.5 g, 4 mmol) and potassium
hydroxide (0.25 g, 4 mmol) were mixed with an
equimolar amount of the desired amino acid (4 mmol)
in water. The bright yellow solution was heated at
40 C. After 15 min a solution of zinc acetate (0.88 g,
4 mmol) in methanol (20 mL) was added and the
cloudy mixture heated for a further 45 min at 60 C.
The solution was allowed to cool and the product
collected, washed with ethanol and diethyl-ether. The
product was then re-suspended in distilled water
(150 mL) and stirred for 3 h. The remaining solid
was recovered by filtration, washed with ethanol and
diethyl-ether and dried in-vacuo.
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Aqua-salicylidenealanine-zinc
Expected for C12H9NO4Zn.H2O: C, 41.05; H, 4.48; N,
4.79%: Found C, 41.05; H, 4.55; N, 4.70% m (cm-1)
3400–3200 (OH); 1,635 (C=N); 1,595 (COO); 1,390
(CO). dH (250 MHz; solvent (CD3)2SO) 8.3 (s, 1H,
CH=N), 7.1 (m, 2H, arom), 6.7 (d, 1H arom), 6.5 (t, 1H
arom), 3.7 (q, 1H, CH), 1.3 (d, 3H, –CH3).
Aqua-salicylideneglycine-zinc
Expected for C9H9NO4Zn: C, 41.49, H, 3.48; N,
5.38%. Found C, 41.32; H, 3.23; N, 5.15%. m (cm-1)
3350–3200 (OH); 1,630 (C=N); 1,595 (COO); 1,390
(CO). dH (250 MHz; solvent (CD3)2SO) 8.3 (s 1H
CH=N), 7.1 (m, 2H, arom), 6.5 (d, 1H arom), 6.4 (t, 1H
arom), 3.0 (d, 2H, –CH2–)
Aqua-salicylideneleucine-zinc
Expected for C13H17NO4Zn: C, 49.31; H, 5.41; N,
4.42% Found C, 48.81; H, 5.22; N, 4.33%. m (cm-1)
3330–3100 (OH); 1,630 (C=N); 1,580 (COO); 1,390
(CO). dH (250 MHz; solvent (CD3)2SO) 8.2 (s 1H
CH=N), 7.1 (m, 2H, arom), 6.5 (d, 1H arom), 6.4 (t, 1H
arom), 3.6 (q, 1H, CH), 1.5 (br m, 3H, CH2 and CH),
0.9 (dd, 6H, –CH3).
Preparation of copper complexes
Salicylaldehyde (0.5 g, 4 mmol) andpotassiumhydrox-
ide (0.25 g 4 mmol) were mixed with an equimolar
amount of the desired amino acid (4 mmol) in water
(15 mL). The bright yellow solution was heated at
40 C. After 15 min a solution of copper acetate
(0.80 g, 4 mmol) in ethanol (20 mL) was added and
the green mixture heated for a further 3 h at 60 C. The
solution was reduced by 80% and the solution left
overnight to allow precipitation. The product was
collected and washed with ethanol. The product was
then re-suspended in the minimum amount of water
filtered and re-precipitated with ethanol. The resulting
solid was recovered by filtration, washed with ethanol
and diethyl-ether and dried in vacuo.
Aqua-salicylidenealanine-copper
Expected for C10H11NO4Cu.H2O: C, 41.31; H, 4.51;
N, 4.82%: Found C, 41.52; H, 3.80; N, 4.83% m (cm-1)
3500–3200 (OH); 1,635 (C=N); 1,595 (COO); 1,390
(CO).
Bis-(aqua-salicylideneglycine-copper)
Expected for C18H18N2O8Cu2.H2O: C, 40.38; H, 3.76;
N, 5.23%: Found C, 40.27; H, 3.66; N, 5.25% m (cm-1)
3300–3100 (OH); 1,635 (C=N); 1,600 (COO); 1,395
(CO).
Aqua-salicylideneleucine-copper
Expected for C13H17NO4Cu: C, 49.59; H, 5.44; N,
4.45% Found C, 49.95; H, 5.39; N, 4.38%. m (cm-1)
3330–3100 (OH); 1,630 (C=N); 1,600 (COO); 1,400
(CO).
Preparation of 5-(p-
sulfophenylazo)salicylidenealanine-zinc
Sulfanilic acid (8.65 g, 0.045 mol) and sodium carbon-
ate (2.65 g, 0.025 mol) were dissolved in 50 mL of
distilled water with heating (*60 C). Once the
solution stopped effervescing and became clear it was
cooled to 15 C. To this solution was added an aqueous
solution of sodium nitrite (3.7 g, 0.0535 mol, 10 mL).
The initial orange solution turned cloudy and white.
This mixture was poured onto 60 g of crushed ice
containing 10.5 mL of concentrated HCl. The diazo-
tised sulfanilic acid was added to a cooled solution of
salicylaldehyde (6 g, 0.05 mol in 60 mL of 3 M
NaOH). The resulting yellow suspension was stirred
for 3 h at 5 C. The mixture was then heated to 80 C
and held there for 45 min. The solution was allowed to
cool to room temperature whereupon an orange precip-
itate forms. This was collected washed with a small
amount of cold water, ethanol and diethyl ether.
Sodium 5-(p-sulfophenylazo-)salicylaldehyde
Expected for C13H9N2O5SNa.2H2O: C, 42.88; H,
3.60; N, 7.69%: Found C, 43.57; H, 2.17; N, 7.41% m
(cm-1) 1,660 (C=O). dH (250 MHz; solvent (CD3OD)
9.9 (s 1H CHO), 8.1 (br s, 1H, arom), 7.95 (br d, 1H
arom), 7.5 (d, 2H, arom–sulfanilic group), 7.0 (br d,
1H, arom), 6.8 (d, 2H, arom -sulfanilic group).
5-(p-sulfophenylazo-)salicylaldehyde (0.6 g,
2 mmol) dissolved in methanol (40 mL) was added
to an ethanolic potassium hydroxide solution (1%,
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25 mL). To this solution was added alanine
(0.0.267 g, 3 mmol) dissolved in the minimum
amount of water. The mixture was heated at 45 C
for 15 min. Zinc acetate (0.647 g, 3 mmol) dissolved
in methanol (30 mL) was added and the mixture
heated to 60 C for 45 min. The volume of the
solution was carefully reduced and an orange precip-
itate formed. This was collected, redissolved in
methanol (with warming) and reprecipitated by tritu-
ration with di-ethyl ether.
Sodium 5-(p-sulfophenylazo-)salicylidenealanine-
zinc
Expected for C16H15N3O7SNaZn.H2O: C, 38.46; H,
3.43; N, 8.41%: Found C, 38.06; H, 2.81; N, 8.05% m
(cm-1) 1,645 (C=N). dH (250 MHz; solvent (CD3OD)
8.4 (s 1H CH=N), 7.9 (m, 6H, arom), 7.0 (d, 1H,
arom), 4.0 (q, 1H, CH), 1.5 (d, 3H, Me).
pH stability studies
The desired metal complex (0.2 mmol) was dissolved
in aliquots of dilute HCl (10 mL) which had been
carefully adjusted to pH’s of 1, 2, 3, 4, 5, 7 respec-
tively. The solutions were stirred for 3 h at 60 C. The
u.v.-visible spectrum (250–800 nm) was then recoded.
The desired metal complex (0.2 mmol) was dis-
solved in aliquots of dilute HCl (10 mL) which had
been carefully adjusted to pH 1.5 or 2.5. Octanol
(10 mL) was then added and the solutions stirred. At
2 min intervals the octanol layer was removed and its
u.v.-visible spectrum (250–800 nm) recorded.
Formalin induced colonic inflammation—
protocols and validation (modified from Walsh
et al. 1987)
Dosage
BK:A mice (25–30 g) received 0.2 mL of formalin
(0.4, 0.8, 1.0, and 2.0%) intrarectally. Instillation was
performed using a trocar needle inserted 2 cm prox-
imal to the anus. One group received 0.2 mL of 0.9%
saline intrarectally. Animals were sacrificed 3 days
and 5 days later and the percentage tissue water
content of the colonic tissue determined. Colons were
examined for signs of inflammation using a scoring
system. Six mice were used.
Time course
BK:A mice (25–30 g) received 0.2 mL of 0.8%
formalin intrarectally. Instillation was performed
using a trocar needle inserted 2 cm proximal to the
anus. Test animals were killed at hourly intervals.
Control animals, groups of six, received 0.2 mL of
0.9% saline intrarectally and were killed at the same
time as the test animals. Time points studied were 0, 1,
2, 3, 4 and 5 h and the percentage tissue water content
of the colonic tissue determined. Ten mice were used.
The effect of intrarectal administration of 5-ASA,
prednisolone, ZnSA, CuSA and zinc chloride
on formalin induced colonic inflammation
5-ASA
Male BK:A mice (20–25 g) in drug-treated groups
received intrarectal administration of 0.2 mL of
5-ASA (15, 30, 150 mg kg-1) dissolved in 0.02 M
sodium hydroxide using a trocar needle. Insertion was
2 cm proximal to the anus. A control group received
0.2 mL of 0.2 M sodium hydroxide intrarectally. Drug
or vehicle was administered 3 days prior to, on the day
of, and 1 day after formalin challenge. Colonic
inflammation was induced via the local instillation
of 0.2 mL of 2.0% formalin using a trocar needle
inserted 2 cm proximal to the anus. A control group
received 0.2 mL of 0.9% saline intrarectally. All
animals were killed 2 days after formalin challenge.
Colons were dissected out and examined for signs of
inflammation using a graded scoring system (vide
infra) and the percentage tissue water content calcu-
lated. Colonic tissue samples were frozen to assay for
myeloperoxidase activity (vide infra). Groups of eight
mice were used.
Prednisolone
Male BK:A mice (20–25 g) in drug-treated groups
received i.p. injections (0.2 mL) of prednisolone (15,
30 mg kg-1 in 20% ethanol). One group received i.p.
injections of 20% ethanol. Drug or vehicle was
administered daily 3 days prior to on the day of and
1 day after formalin challenge. Colonic inflammation
was induced via the local instillation of 0.2 mL of
2.0% formalin using a trocar needle. Insertion was
2 cm proximal to the anus. A control group received
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0.2 mL of 0.9% saline intrarectally. All animals were
killed 2 days after formalin challenge. Colons were
dissected out and examined for signs of inflammation
using a graded scoring system and the percentage
tissue water content calculated. Colonic tissue samples
were frozen to assay for myeloperoxidase activity.
Groups of eight mice were used.
ZnSA/CuSA/ZnCl2
Male BK:A mice (20–25 g). in treatment groups
received either ZnSA, CuSA or zinc chloride (1.0 and
5.0 mol kg-1) intrarectally using a trocar needle.
ZnSA and CuSA were dissolved in 0.02 M sodium
hydroxide (0.2 mL) whereas zinc chloride was pre-
pared in distilled water (0.2 mL). Insertion was 2 cm
proximal to the anus. A control group received 0.2 mL
of 0.2 M sodium hydroxide intrarectally. Drug or
vehicle was administered twice daily 3 days prior to,
on the day of and 1 day after formalin challenge.
Colonic inflammation was induced via the local
instillation of 0.2 mL of 2.0% formalin using a trocar
needle. Insertion was 2 cm proximal to the anus. A
control group received 0.2 mL of 0.9% saline intrarec-
tally. All animals were killed 2 days after formalin
challenge. Colons were dissected and examined for
signs of inflammation using a graded scoring system
and the percentage tissue water content calculated.
Colonic tissue samples were frozen to assay for
myeloperoxidase activity for the ZnSA groups.
Groups of twelve mice were used.
The effect of oral administration of ZnSA, CuSA
and zinc chloride on formalin induced colonic
inflammation
Male BK:A mice (20–25 g). in treatment groups
received either ZnSA, CuSA or zinc chloride (1.0 and
5.0 mmol kg-1) orally. ZnSA and CuSA were sus-
pended in 0.2 mL of 0.9% saline whereas zinc
chloride was dissolved in distilled water. A control
group received 0.2 mL of 0.9% saline for ZnSA and
CuSA and 0.2 mL of distilled water for the zinc
chloride group. Drug or vehicle was administered
twice daily 3 days prior to, on the day of and 1 day
after formalin challenge. Colonic inflammation was
induced via the local instillation of 0.2 mL of 2.0%
formalin using a trocar needle. Insertion was 2 cm
proximal to the anus. A control group received 0.2 mL
of 0.9% saline intrarectally. All animals were killed
2 days after formalin challenge. Colons were dis-
sected and examined for signs of inflammation using a
graded scoring system and the percentage tissue water
content calculated. Colonic tissue samples were frozen
to assay for myeloperoxidase activity for the ZnSA
group. Groups of six mice were used for the studies on
ZnSA and CuSA and seven mice for the study using
zinc chloride.
Trinitrobenzenesulfonic acid (TNB) induced
colitis in Rats (Morris et al. 1984, 1989)
Dosage
Under light anaesthesia, male Wistar rats (200–250 g)
received 0.25 mL of solution intrarectally using a
trocar needle. Insertion was around 7 cm proximal to
the anus. An ethanol control group received 0.25 mL
of 50% ethanol. Test animals received, 0.25 mL of
60 mg kg-1 TNB solution, 0.50 mL of 60 mg kg-1
TNB solution and 0.25 mL of an 120 mg kg-1 TNB
solution in 50% ethanol respectively. A second study
group received 0.25 mL of 80 mg kg-1 TNB solution
or 0.25 mL of an 120 mg kg-1 TNB solution dis-
solved in 50% ethanol using a modified trocar needle
(vide infra). An ethanol control group received
0.25 mL of 50% ethanol using the modified needle.
Animals were killed at the stipulated time and
examined for signs of inflammation using the scoring
system.
Time course
Under light anaesthesia, male Wistar rats (200–250 g)
received 0.25 mL of solution intrarectally using a
modified trocar needle. Insertion was around 7 cm
proximal to the anus. Test animals received 0.25 mL
of an 80 mg kg-1 TNB solution in 50% ethanol.
Control animals received 0.25 mL of 50% ethanol.
The time points studied were 12, 24 h and 3, 5 and
7 days. Animals were killed a week later and exam-
ined for signs of inflammation using the scoring
system (vide infra).
Modifications to the trocar needle
A length of narrow plastic tubing was inserted over a
4 cm long trocar needle to produce a final length of
428 Biometals (2017) 30:423–439
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7 cm. The end of the tubing was sealed and holes were
made down the sides of the tubing; one hole either side,
4 mm apart to a length of 2.4 cm from the tip. This
ensured good penetration and good fluid distribution.
The effect of oral administration of SASP, ZnSA
and sodium 5-(p-sulfophenylazo-)-
salicylidenealanine-zinc (AzZnSA) on TNB
induced colonic inflammation
Colitis was induced in male Wistar rats (180–220 g)
under light anaesthesia via the rectal instillation of
0.25 mLof an80 mg kg-1 solutionofTNBdissolved in
50% ethanol using a modified trocar needle. Instillation
was 7 cm proximal to the anus. One control group
received 0.25 mL of 50% ethanol intrarectally, another
control group received 0.25 mL of 0.9% saline intrarec-
tally. The following experiments were not conducted
blind. Male Wistar rats (180–220 g) in drug treatment
groups received sulfasalazine, ZnSA or AzZnSA orally
(1.5 9 10-4, 3.0 9 10-4, 7.5 9 10-4 mol kg-1 per
day) in 1% hydroxyethylcellulose. A control group
received 0.5 mL of 1% hydroxyethylcellulose. Drug or
drug vehicle was administered one day prior to, on the
day of and daily following the induction of colitis. Five
rats were used in this study. The lowest dose of SASP
used here is based on the clinically used dosage
(60 mg kg-1 eq for rats). Animals were killed 7 days
after TNB instillation. Colons were dissected out and
examined for signs of inflammation using the graded
scoring system. Colonic tissue samples were frozen to
assay for myeloperoxidase activity.
Scoring system
For studies using the formalin induced colitis a
modified scoring system base on that reported by
Morris et al. (TNBmodel) was employed (Morris et al.
1984, 1989) where
0 No signs of mucosal inflammation,
1 Erythema,
2 Any two of erythema, oedema or diarrhoea,
3 Any three of erythema, oedema, diarrhoea, pin
head ulceration or stricture.
4 All of the above signs plus pronounced or clearly
defined ulceration.
5 As 3 plus severe, extensive ulceration and/or
severe structural damage.
Measurement of oedema
A sample of colonic tissue (2 cm) was removed and
weighed when wet. This is dried on a balance until it
reaches constant weight (typically 45 min), from
which the dry weight and percentage water is
calculated.
Myeloperoxidase assay: MPO activity was con-
ducted using the modified method of Bradley et al.
1982). 2 cm of colon was finely divided in 1 mL of
0.5% hexadecyltrimethyl-ammonium bromide
(HTAB) in 50 mM K3PO4 buffer. The tissue was
transferred to a homogenising tube taking care to
transfer all materials (1 mL HTAB solution rinse was
applied) and the mixture homogenised on ice. The
mixture was transferred to assay tubes. All containers
were rinsed with a further 1 mL of HTAB solution to
give a final volume of 3 mL. The sample was sonicated
for 10 s in an ice bath and then subjected to a three
freeze thaw cycles in a dry ice bath. The sample was re-
sonicated and then centrifuged. 1 mL of the super-
natant was added to 2.9 mL of 50 mM K3PO4 buffer
(pH 6) containing 0.167 mg mL-1 of o-dianisidine di-
hydrochloride and 0.0005% hydrogen peroxide. The
reaction was stopped after 5 min by the addition of
0.1 mL of 1.2 M hydrochloric acid. The absorbance of
the resulting solution was measured at 400 nm.
Myeloperoxidase activity and percentage tissue
water values were expressed as the mean ± standard
error of the mean. Colitic scores were expressed as
median and range. In the figures (vide infra), a large
error bar usually indicates one value outwith the
population around the median. Group comparisons
were done using the Mann–Whitney U test. Where
more than two groups were involved the results were
analysed for difference using one-way analysis of
variance and the significant differences between
groups were examined by the Newman-Keuls range
test at 5% level of significance. Asterisks denote
significance to colitic controls unless otherwise stated.
Results and discussion
Synthesis and structure
A large number of Schiff base complexes of zinc and
copper havenowbeen reported. These are formedby the
condensation of an aldehyde and amine in the presence
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of the desired metal cation, typically as the acetate.
Although we wished to maintain a therapeutic link with
5-ASA (Fig. 2), we did not wish to use the amine
functionality on 5-ASA as the basis of the Schiff’s base
linkage as we envisaged using it later in the further
development of the system to incorporate further active
organic moieties (vide infra). We thus turned our initial
attention to the carboxylate group as a primary site for
chemical modification, but in its reduced form i.e. the
aldehyde, as this not only provides us with a suit-
able commercially available aldehyde i.e. salicylalde-
hyde (Fig. 2) it introduces a hydrolytically
unstable bond into the complex. A hydrolysis reaction
occurring in vivo would allow the complex to degrade
and slowly release the active agents brought together in
our formulation. A number of the salicylaldehyde based
compounds chosen for development have been struc-
turally characterised elsewhere (Ueki et al. 1969;Warda
1998;Garcia-Rasoet al. 2000; Shovaet al. 2000;Li et al.
2007). These demonstrate a range of structural forms
depending on the nature of the co-crystalline entities.
However, it is evident that all complexes of this type
have a common core motif (1, Fig. 2), one which will
persist in aqueous solution.
When constructing and testing poly-modal com-
pounds it is preferable to build them sequentially. Thus
the first stage is to construct complexes, which contain
salicylaldehydeandeither copperor zinc.To stabilise the
motif we still require a non-active amine and we have
elected to use simple amino acids in the initial survey.
Although we were successful in preparing a number of
simple Schiff base complexes of copper and zinc
(Fig. 2), without the stabilising influence of the chelated
metal the simple condensation products of the amino
acid and salicylaldehyde were not stable in out hands.
This observationmitigates against an investigationof the
simple condensates as an independent control.
Acid tolerance
StudiesusingPENTASAhavedemonstrated that even
when the release of the anti-colitic components is
initiated in the stomach sufficient quantities of the active
agent can still be achieved in the colon (Christensen
et al. 1987). However, it would be preferable if
significant amounts of the orally administered agent
traverses the stomach and reaches the inflamed colon.
Since the pH of the stomach can vary from 1.0 to 3.5 in
the fed state rising to 4.0–5.0 in the unfed state, it is
important to understand how these Schiff base com-
plexes (Fig. 3) breakdown under different pH condi-
tions (Gruber et al. 1987). This knowledge will make it
possible to select putative compounds based on their
predicted behaviour in the stomach.
Fig. 2 The synthetic
scheme. The products form
in most cases as monomers
(1) or oligomers (Ueki et al.
1969; Warda 1998; Garcia-
Raso et al. 2000; Shova et al.
2000; Li et al. 2007).
Oligomerisation occurs via
bridging carboxylate
groups. CuSA and CuSG
have crystallographically
characterised dimeric forms
(Li et al. 2007; Warda 1998)
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A simple spectrophotometric analysis of the iso-
lated metal complexes and salicylaldehyde demon-
strate that the Schiff base complexes have an
absorption maxima at 350 nm whereas the free
salicylaldehyde has a maxima at 325 nm respectively.
Thus by monitoring solutions of a given complex as a
function of pH it is possible to show at which pH
complex degradation is significant (Fig. 3). The study
shows that both compounds will degrade at pH’s
prevalent in the stomach. However, CuSAwould seem
to be more acid tolerant. This study does not provide
any details on the rate of degradation. As such moving
to an octanol water system allows for time dependant
sampling. Subjecting the compounds to solutions at
very low pH accelerates degradation to rates which
can be observed by spectrophotometric means. From
this study it can be seen that degradation of ZnSA is
rapid (t * mins) whereas CuSA is much longer
lived (Fig. 3). This study suggests that the copper
complex has a longer lifetime and is better placed to
traverse the hostile environment either as a suspended
material or adsorbed onto larger moieties. It is
notable that the choice of metal centre can have a
profound effect on the degradation process.
The effect of ZnSA and CuSA on Formalin
induced colonic inflammation
Formalin is one of the components of immune complex
mediated colitis and is capable of initiating an inflam-
matory response in its own right. This observation
made the formalin induced colonic inflammation
(FICF) model particularly appropriate for the needs
of this study (Walsh et al. 1987). However, prior to be
being challenged with any of the potential anticolitic
compounds we required to optimise the model to
identify an appropriate protocol for the induction of
colonic inflammation.BK:Amice received an intrarec-
tal instillation of formalin (0.0, 0.4, 0.8, 1.0 and 2.0%)
in two groups. The first group were sacrificed after
3 days and the second group after 5 days after which
the colonic tissues fromboth groupswere examined for
changes in their colitic score (Fig. 4). The study
indicates that a suitable inflammatory response was
present at 3 days but that the response had dissipated at
day 5. Macroscopic features associated with inflam-
mation were observed during this test at day 3 i.e.
oedema (incidence 4/6), mucus (3/6) and ulceration (1/
6). Although the lower concentrations of formalin had
no effect on tissue water content at day 3 or 5, animals
receiving 0.8% formalin did show a median colitic
score of 1 at day 3 indicating that the tissue showed
either erythema, excess mucus or oedema. A second
validation studywas conducted (Fig. 4) using a shorter
time period (0–5 h) but with a fixed concentration of
formalin (0.8%). This shows that the inflammatory
response initiated by formalin presents very quickly in
the model. A model in which the induction time for
inflammation is short (*2 h) and can last days is
particularly appropriate to the needs of this study.
We wished to model a simple treatment regimen
which modelled therapeutic practice and as such
Fig. 3 Left Spectrophotometric analysis of ZnSG (black dia-
mond) and CuSA (black square) as a function of pH. ZnSA is
moderately less acid tolerant. However, at pH’s[4metal complex
(kmax 350) will persist in solution. At pH’s below 3 the complex
hydrolyses to release salicylaldehyde (kmax 325): Right The
hydrolysis of ZnSA (black diamond) and CuSA (black square) in
an octanol water mixture at pH 1.5 and 2.5 estimated as the
increase in free salicylaldehyde (kmax 325) in the octanol layer
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decided to administered drug or vehicle 3 days prior
to, on the day of, and 1 day after formalin challenge.
Using the data above (Fig. 4) we opted to employ the
higher concentration of formalin (2.0%) over a 2 day
period. These compromises would allow inflammation
to be established quickly and be sustained during the
treatment period. The anti-colitic properties of ZnSA
and CuSA were thus tested using the FICF model. The
study was controlled using 5-ASA, prednisolone and
zinc chloride (ZnCl2). 5-ASA, ZnSA, CuS and ZnCl2
at equimolar amounts were administered intrarectally
whereas prednisolone was administered by i.p. injec-
tion. Samples retrieved from the colons were used to
calculate the tissue water content, myeloperoxidase
assay and colitic score (Fig. 5). The myeloperoxidase
assay did not perform in an acceptable manner in the
presence of CuSA and consequently the data was not
recorded for this compound. Prednisolone signifi-
cantly (p\ 0.05) lowers the tissue water content of
colonic tissue compared to formalin. In contrast only
5-ASA has a significant effect (p\ 0.05) on
myeloperoxidase activity. However, the analysis of
the overall anti-colitic behaviour of the compounds
estimated using the scoring system not only confirms
the efficacy of 5-ASA but supports the conclusion that
high dose ZnSA significantly reduces (p\ 0.05) the
median colitic score compared to that of the formalin
treated group. In contrast the corresponding copper
species had little effect on any of the parameters
measured. The pH studies discussed above (Fig. 3)
show that ZnSA has the more rapid degradation profile
which suggests that significant amounts of simple zinc
salts might be being generated in the colitic zone
during analysis. Testing this hypothesis by the appli-
cation of ZnCl2 instead of ZnSA (Fig. 5) clearly shows
that zinc alone is having little effect. It is evident that it
is the organic component or metal complex which is
giving rise to the positive anticolitic result. The study
was reformulated and the compounds administered
orally (Fig. 6). The 5-ASA and prednisolone controls
were not included at this juncture as we were
particularly interested in the direct comparison of the
administration route of the two compounds. Consis-
tent with the above CuSA still shows little evidence of
any anticolitic behaviour by oral administration.
However, ZnSA demonstrated improves anticolitic
properties when administered orally. Not only did
ZnSA show a significant effect through its impact on
themedian colitic score, there is now evidence that it is
having a beneficial effect on myeloperoxidase activity
at higher dosages. Once again we could not identify
any anti-colitic properties for ZnCl2 alone. Thus
despite the poor stability profile of ZnSA (Fig. 3) it
would seem that a portion of the compound is reaching
the colon intact where it has a beneficial effect on the
inflammatory process. Although key data points do
indicate that ZnSA is a good lead compound at no
point do we see any evidence for a dose related
response at this juncture.
It should be noted that the compounds (ZnSA,
CuSA) being tested above are bimodal i.e. they release
zinc/copper and a 5-ASA precursor into the region of
Fig. 4 Top the effect of intracolonic administration of 0.8%
formalin (solid column; n = 10) on percentage tissue water
content during a period of five hours. Saline (0.9%) control
(open column n = 6). Results are presented as mean ± SEM.
Asterisks denote significant difference from saline control
(p\ 0.05; Mann–Whitney U test). Bottom the effect of
intracolonic administration of formalin (0.0–2.0%) on percent-
age tissue water content at 3 and 5 days during a period of 5 h.
n = 6 for all groups. Asterisks denote significant differences
between groups (p\ 0.05); one way analysis of variance,
Neuman–Keuls range test
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colonic insult. Based on the data it was decided to
abandon copper as a potential anti-colitic moiety and
focus our attention on zinc. The design and synthesis
of ZnSA (Fig. 2) employed alanine as a redundant
amine for Schiff base formation. However, the
methodology which allows the alanine moiety to be
replaced by a biologically active amine is well
established. Indeed the synthesis of the penicillamine
and cysteine adducts have been reported (MacDonald
et al. 1979, 1982; Chohan et al. 2007). Thus of greater
interest and potentially greater impact is to strengthen
the link between 5-ASA and our salicylidene moiety
(Fig. 2) by modifying the salicylaldehyde moiety.
Trimodal complexes
The desire to focus on further modification to the
salicylaldehyde ring is driven by the possibility of
introducing an azo-linkage into the compound.
Electronic effects will drive this modification to
the 5 position on the aryl ring (Fig. 7) and as such
post modify the salicylaldehyde into a more
apposite 5-ASA analogue. However the introduc-
tion of an azo group introduced at this position
means that we will have effectively stabilised a
Schiff base complex of a sulfasalazine analogue
(Fig. 7).
Fig. 5 The effect of intrarectal 5-ASA, prednisolone i.p.,
intrarectal ZnSA, CuSA and ZnCl2 on percentage tissue water
content (top), myeloperoxidase activity (middle) and colitic
score (bottom) 2 days after intrarectal formalin (2%) challenge.
Drug was administered 3 days prior to, on the day of and 1 day
after formalin challenge. Groups studied were saline control,
formalin and vehicle and compound. The number in each group
is identified on the data associated with tissue water content.
Results are presented as mean ± SEM. for tissue water content
and myeloperoxidase activity and as median and range for the
colitic score. Asterisks denote significant difference to control
(p\ 0.05); one way analysis of variance, Neuman–Keuls range
test. The poor performance of prednisolone in this study is
ascribed to the different method of administration and how this
modulates the dosage applied
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The studies above using BK:A mice confirmed that
the zinc compounds displayed anticolitic activity and
furthermore that they were active via the oral route.
However, modelling colitis is extremely difficult and
care must be exercised not to rely too heavily on
favourable results from a single model. As such it was
decided to introduce a second animal model for the
testing of the second generation compounds, moving
to the trinitrobenzenesulphonic acid (TNB) mediated
colitic model using larger Wistar rats (Morris et al.
1984, 1989). Moving to a larger animal had the added
advantage that there would be more material and thus
there would be less variation within the data. Since the
trimodal compound being tested here has greater
similarity to sulfasalazine (SASP) we also replaced
5-ASA with SASP as the control in these tests.
However, prior to be being challenged with any of the
anticolitic compounds we are again required to
optimise the model to identify an appropriate protocol
for the induction of colonic inflammation. Wistar rats
received an intrarectal instillation of TNB at a variety
of concentrations and volumes (Fig. 8). At low
dosages (60 mg mL-1) we observed that the inci-
dence and rate of ulceration were inconsistent. At
higher concentrations (120 mg mL-1) the mortality
rate was too high. This was thought due to the
extremely localised introduction of the TNB solution
to the colon. Consequently a modified needle was
employed which allowed the solution to be more
evenly distributed within the colon during TNB
administration. The application of TNB using the
modified needle gave agreeable results at
80 mg mL-1 TNB, however, the mortality rate at
120 mg mL-1was still inferior and as such we elected
to go forward with a dose regimen of 80 mg mL-1.
The time course supports the view that 80 mg mL-1 is
Fig. 6 The comparison of intrarectal and oral administration of
ZnSA, CuSA and ZnCl2 on percentage tissue water content
(top), myeloperoxidase activity (middle) and colitic score
(bottom) 2 days after intrarectal formalin (2%) challenge. Drug
was administered 3 days prior to, on the day of and 1 day after
formalin challenge. Groups studies were saline control, formalin
and vehicle and compound. The number in each group is
identified on the data associated with tissue water content.
Results are presented as mean ± SEM. for tissue water content
and myeloperoxidase activity and as median and range for the
colitic score. Asterisks denote significant difference to control
(p\ 0.05); one way analysis of variance, Neuman–Keuls range
test
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an appropriate concentration. All the animals
(2 9 6 9 6, Fig. 8) survived to day seven. The data
at 5 and 7 days indicated that the inflammatory model
has a long duration. Consequently, we elected to
employ a 1 week gestation period.
The SASP treated group showed a significant
increase in the colitic score compared to the
TNB/drug vehicle group (Fig. 9) with the median
scores falling in line with the dosage. This is
confirmed by a more in-depth analysis of incidence
of tissue adhesion, colon distension and abdominal
distension which indicated that SASP affords symp-
tomatic control of TNB-mediated colitis (Fig. 10).
Myeloperoxidase activity in all groups receiving TNB
was significantly higher than the saline and ethanol
control groups. However, there was no significant
reduction in myeloperoxidase activity between the
TNB drug vehicle group and the drug treated group.
Thus the reduction in colitic score produced by SASP
is not paralleled by a reduction in neutrophil activity.
This is consistent with the observation that treatment
with 5-ASA (100 mg kg-1) produces significant
reductions in colonic damage, colon wet weight and
the incidence of adhesion but also did not affect
colonic myeloperoxidase activity or LTB4 synthesis
(Wallace 1988).
Fig. 7 The synthesis of the trimodal zinc complex AzZnSA. The compound now incorporates zinc, a 5-ASA precursor and an azo
entity which models the active moiety in SASP
Fig. 8 Left the effect of intracolonic administration of 50%
ethanol (open columns) and TNB in 50% ethanol at various
concentrations and volumes (solid column) on colitic score.
Results are represented as median and range. Right the time
course of intrarectally administered ethanol (50% open
columns) and TNB (80 mg mL-1 in 50% ethanol) on colitic
score. n = 5 for all groups. Asterisks denote significant
differences between groups (*p\ 0.05, **p\ 0.01); one way
analysis of variance, Neuman–Keuls range test
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Treatment with ZnSA orally did not produce a
significant reduction in colitic score or reduction in
myeloperoxidase activity (Fig. 9) in the TNB induced
colonic inflammation model. This observation contrast
markedly with the data obtained earlier in the mouse
model (Fig. 6). In the formalin induced mouse model
neutrophil flowwas rapidandof short durationand is thus
is probably a good marker for the determination of the
inflammatory response. In the TNB model, although
neutrophil influx is rapid it is maintained for 7 days
(Fig. 8). This suggests that a potent anti-inflammatory
would be required to inhibit myeloperoxidase activity in
the TNBmodel. In contrast to ZnSA, AzZnSA produced
a significant reduction in the median colitic score
compared to themedian values for the TNB/drug vehicle
group (Fig. 9). The group treatedwith the highest dosage
of AzZnSA demonstrated an absence of tissue adhesion,
colonic distension andabdominal dissention compared to
the TNB group (Fig. 10). However, similar to ZnSA,
AzZnSA was not effective in reducing myeloperoxidase
activity. It can be concluded that AzZnSA was effective
in reducing the symptoms of colitis but not neutrophil
activity. This observation is similar to that observed for
SASP in the same model. Plotting the individual scores
for tissue adhesion, colonic distension and abdominal
distension in the SASP and AzZnSA treatment groups
suggest there is a similar dose related profile for the two
species. It can be concluded that the diazotisation of the
Schiff base complex ZnSA has produced a more potent
compound and one comparable to SASP. The reasons for
this are probably threefold. The azo group is assisting in
the delivery of the complex to the colon (c.f SASP), the
diazotisation reaction has chemically altered the salicy-
laldehyde into a reduced form of 5-ASA and finally the
incorporationof sulfanilic acid, similar to a sulfapyridine,
may be acting to prevent injury (Cho et al. 1987).
Concluding remarks
The treatment of ulcerative colitis is limited to two
main approaches: corticosteroid therapy and SASP
Fig. 9 Left the effect of oral
SASP, ZnSA and AzZnSA
(1.5 9 10-4, 3.0 9 10-4
and 7.5 9 10-4 mol kg-1)
on myeloperoxidase activity
(top) and colitic score
(bottom) 7 days after
induction of colonic
inflammation with TNB
(0.25 mL 80 mg kg-1 in
50% ethanol). n = 5. Drug
was administered one day
prior to, on the day of and
daily after induction of
colitis. Groups studies were
saline control, ethanol
control, TNB and vehicle,
SASP, formalin and vehicle
and compound. Results are
presented as mean ± SEM.
for myeloperoxidase
activity and as median and
range for the colitic score.
Asterisks denote significant
difference to control
(p\ 0.05); one way
analysis of variance,
Neuman–Keuls range test.
The median colitic score (3)
of the TNB vehicle group in
the ZnSA study is low
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therapy. In the case of resistance to these azathio-
prine is administered. Thus there is still a need for
new approaches to the treatment of this condition.
The desire to have orally administered drugs
requires the synthesis of species which can survive
the pH conditions of the stomach. We have
approached this problem here by designing Schiff
base species which serve to protect the active agent
during transit. We focussed our attention here on
copper and zinc. While we have observed that zinc
performs better than copper more effort is required
to screen alternative metal centres which can
stabilise Schiff base linkages.
We have been able to show that orally administered
ZnSA at 1.0 9 10-3 mol kg-1 significantly reduces
the colitic score (60%) and myeloperoxidase activity
(58%) in an acute colitis model (mouse). However,
sadly this compound does not provide any significant
protection in a more chronic (TNB induced colitic)
model. It is possible that ZnSA only functions in acute
colitis. Diazotisation of the salicylaldehyde generates
a better 5-ASA analogue and a compound which also
better models SASP. This species is observed to
provide anticolitic properties in the chronic TNB
induced colitis model commensurate with SASP.
Significantly, the trimodal compound designed here
while showing great promise can be modified much
further and there remains great scope for further
development. For example, this study has relied
exclusively on simple non bio-active amino acids
such as alanine to furnish the Schiff base linkages.
This moiety could easily be replaced by more active
amino acids species such as cysteine and penicil-
lamine which have antioxidant properties in their own
right. Alternatively, the incorporation of species such
as lipoamide might allow the compounds to be
specifically targeted to the gut microfloral as a release
mechanism. Finally the sulfanilic acid used in the
diazotisation reactions could itself be replaced by
more bioactive aryl species. Alternatively the analino
function on the sulfanilic acid can itself be used to
carry a further bioactive entity (c.f. SASP). If any of
these modification can be shown to enhance the anti-
colitic properties of the motif reported here, then the
compound generated could potentially be able to
outperform the anti-colitic properties of SASP.
Compliance with ethical standards
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